Please use this identifier to cite or link to this item:
Title: Synthesis and Binding Mode of Heterocyclic Analogs of Suramin Inhibiting the Human Basic Fibroblast Growth Factor
Authors: Manetti, Fabrizio 
V., Cappello
Botta, Maurizio 
Corelli, Federico 
N., Mongelli
G., Biasoli
M., Ciomei
Keywords: Antiangiogenic compounds; Binding mode; Human basic fibroblast growth factor; Molecular docking; Suramin analogues
Issue Date: 1998
Project: None 
The design, synthesis, and biological evaluation of a series of pyrrole and pyrazole congeners 2 of suramin, directed toward the development and identification of new ligands that complex the human fibroblast growth factor (bFGF), thereby inhibiting tumor-promoted angiogenesis, is reported. Compounds 2 were evaluated for their ability to inhibit binding of bFGF to its receptor, in vivo bFGF-induced angiogenesis, and neovascularization of the chorioallantoic membrane in comparison with suramin. These assays showed that ligands 2 exhibit moderate to good activity, comparable to that of suramin, and are less toxic than suramin itself. In this study, affinity data of ligands in combination with the crystal structure of bFGF were used to explain structure-affinity relationships and to gain an insight into the possible mode of ligand-protein interaction. Due to the lack of experimental structural data on the ligand-bFGF complexes, molecular mechanics techniques were used to obtain putative bioactive conformations and to generate docked complexes with the three-dimensional structure of bFGF. These experiments led to suggest that compounds 2 give rise to 1:1 complexes with bFGF through an unprecedented, bidentate attachment of their naphthylsulfonate groups to two main domains, commonly referred to as the heparin binding site and the receptor binding site, on bFGF, thus preventing the interaction of the growth factor with its receptor.
ISSN: 0968-0896
DOI: 10.1016/S0968-0896(98)00052-2
Appears in Collections:Publications

Show full item record

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.